Ironwood Pharmaceuticals traded at $3.54 this Thursday April 2nd, decreasing $0.36 or 9.23 percent since the previous trading session. Looking back, over the last four weeks, Ironwood Pharmaceuticals lost 2.75 percent. Over the last 12 months, its price rose by 160.29 percent. Looking ahead, we forecast Ironwood Pharmaceuticals to be priced at 3.43 by the end of this quarter and at 3.13 in one year, according to Trading Economics global macro models projections and analysts expectations.
Ironwood Pharmaceuticals, Inc. is a gastrointestinal (GI) healthcare company. The Company is focused on the development and commercialization of GI product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC). It operates in human therapeutics business segment. Its product candidate LINZESS (linaclotide) is available to adult men and women suffering from IBS-C or CIC in the United States, and Mexico and to adult men and women suffering from IBS-C in Japan and China. Its linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC in Canada, and to adult men and women suffering from IBS-C in certain European countries.